Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03500-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Dipanjan Karati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, School of Pharmacy, Techno India University, Kolkata, West Bengal, 700091, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Glycogen Synthase Kinase 3, Protein Kinase Inhibitors, Neuroprotective Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 188 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), the most common type of dementia among older adults, is a chronic neurodegenerative pathology that causes a progressive loss of cognitive functioning with a decline of rational skills. It is well known that AD is multifactorial, so there are many different pharmacological targets that can be pursued. According to estimates from the World Health Organization (WHO), 18 million individuals worldwide suffer from AD. Major initiatives to identify risk factors, enhance care giving, and conduct basic research to delay the beginning of AD were started by the USA, France, Germany, France, and various other nations. Widely recognized as a key player in the development and subsequent progression of AD pathogenesis, glycogen synthase kinase-3 (GSK-3) controls a number of crucial targets associated with neuronal degeneration. GSK-3 inhibition has been linked to reduced tau hyperphosphorylation, β-amyloid formation, and neuroprotective benefits in Alzheimer's disease. Lithium, the very first inhibitor of GSK-3β that was used therapeutically, has been successfully used for many years with remarkable results. A great variety of structurally varied strong GSK-3β blockers have been identified in recent years. The purpose of this thorough review is to cover the biological and structural elements of glycogen synthase kinase, as well as the medicinal chemistry aspects of GSK inhibitors that have been produced in recent years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, School of Pharmacy, Techno India University, Kolkata, West Bengal, 700091, India.
- Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata - Group of Institutions, 124, B.L Saha Road, Kolkata, West Bengal, 700053, India.
- Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata - Group of Institutions, 124, B.L Saha Road, Kolkata, West Bengal, 700053, India. swarupananda.mukherjee@nshm.com.
- Department of Pharmaceutical Technology, Bharat Technology, Uluberia, Howrah, West Bengal, 711316, India.
- Department of Pharmaceutical Technology, Bengal College of Pharmaceutical Technology, Dubrajpur, West Bengal, 731123, India.
- Central Ayurveda Research Institute, Kolkata, West Bengal, 700091, India.
ORCID-Profile: Swarupananda Mukherjee
Zitieren
APA
Karati, D., Meur, S., Roy, S., Mukherjee, S., Debnath, B., Jha, S. K., Sarkar, B. K., Naskar, S., & Ghosh, P. (2025). Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03500-1
Vancouver
Karati D, Meur S, Roy S, Mukherjee S, Debnath B, Jha SK, et al. Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03500-1
BibTeX
@article{Karati2025,
author = {Karati, Dipanjan and Meur, Shreyasi and Roy, Souvik and Mukherjee, Swarupananda and Debnath, Biplab and Jha, Sajal Kumar and Sarkar, Biresh Kumar and Naskar, Saheli and Ghosh, Priya},
title = {Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03500-1}
}
EUVIMED